Citation Tools
PDFInflammatory bowel disease
Cost-effectiveness of adalimumab, infliximab or vedolizumab as first-line biological therapy in moderate-to-severe ulcerative colitis
Download to a citation manager
Download the citation for this article by clicking on one of the following citation managers:
- Cite this article as:
- Cost-effectiveness of adalimumab, infliximab or vedolizumab as first-line biological therapy in moderate-to-severe ulcerative colitis